Guided by our patient-centered mission and science-driven strategy, Lustgarten supports flexibility, fearlessness, creative confidence, and a culture of innovation and dedication to scientific rigor. We are breaking down industry silos to drive collaboration and information sharing to advance pancreatic cancer research.
Collaborations Include:
Break Through Cancer
In 2022, Lustgarten Foundation partnered with Break Through Cancer to bring their Team Lab approach that maximizes interdisciplinary collaboration among researchers to pancreatic cancer. The Lustgarten Foundation has invested in two projects, Conquering KRAS and Demystifying Pancreatic Cancer, bringing teams of researchers from five of the nation’s top cancer research centers to boldly tackle two of the biggest challenges in cancer. The Conquering KRAS project is focused on developing effective combination therapy strategies to target KRAS – the driver, and potential Achilles heel, of more than 90% of pancreatic tumors. The Demystifying Pancreatic Cancer project will develop tools that will allow researchers to follow a tumor’s response to therapy during clinical trials – allowing us to understand what factors drive response and resistance to treatments.
Coalition to Accelerate Early Detection of Deadly Cancers
In early 2026, Lustgarten co-founded a first-of-its-kind coalition with leading cancer research organizations, including The Mark Foundation for Cancer Research, American Association for Cancer Research (AACR), Break Through Cancer, and The Honorable Tina Brozman Foundation (Tina’s Wish), to speed the discovery and validation of biomarkers, imaging tools, and data-driven approaches for earlier diagnosis of pancreatic and other lethal cancers. By funding collaborative, multi-institution teams and sharing data across disciplines, the coalition aims to detect disease sooner, when treatment is most effective and survival can improve.
Other funding partnerships:
 |
 |
 |
 |
 |
 |
 |